Granahan Investment Management Invests $1.7M in Beta Bionics

The investment firm acquired a new stake in the medical device company during the third quarter.

Mar. 17, 2026 at 9:10am

Got story updates? Submit your updates here. ›

Granahan Investment Management LLC acquired a new stake in Beta Bionics, Inc. (NASDAQ:BBNX) during the third quarter, purchasing 85,741 shares of the company's stock valued at approximately $1,704,000. Several other institutional investors have also added to or reduced their stakes in BBNX in recent quarters.

Why it matters

Beta Bionics is a clinical-stage medical device company focused on developing automated insulin delivery solutions for people with type 1 diabetes. The company's flagship product, the iLet Bionic Pancreas system, aims to simplify glycemic control by automatically adjusting insulin dosing. Granahan's investment signals confidence in Beta Bionics' technology and potential market opportunity.

The details

Granahan Investment Management acquired the new stake in Beta Bionics during the third quarter. Several other institutional investors, including GPS Wealth Strategies Group LLC, EverSource Wealth Advisors LLC, Strs Ohio, and Ameritas Investment Partners Inc., have also added to or reduced their positions in BBNX in recent quarters.

  • Granahan Investment Management acquired the new stake in Beta Bionics during the third quarter.
  • The investment was disclosed in a regulatory filing on March 17, 2026.

The players

Granahan Investment Management LLC

An investment management firm that acquired a new stake in Beta Bionics, Inc.

Beta Bionics, Inc.

A clinical-stage medical device company focused on developing automated insulin delivery solutions for people with type 1 diabetes.

Got photos? Submit your photos here. ›

The takeaway

Granahan Investment Management's investment in Beta Bionics signals confidence in the medical device company's technology and potential to disrupt the type 1 diabetes management market with its automated insulin delivery system.